Virgo to Use New Funding to Expand its VirgoTrials Platform

Virgo to Use New Funding to Expand its VirgoTrials Platform

Healthcare Tech Outlook | Monday, January 24, 2022

Virgo will use the freshly raised funds to develop the VirgoTrials platform and speed up distribution in the U.S. And around the world.

Fremont, CA: Clinical research is critical to public health because it efficiently gathers information and determines the efficacy and safety of new groundbreaking and life-changing treatments. Virgo Surgical Video Solutions has closed its Series A funding round, led by FCA Venture Partners and includes Tom Williams of Heron Rock Fund, who led the company's seed round, to scale its proprietary solutions for faster clinical trials. Virgo is widely considered the industry leader in recording and organizing endoscopic video data, and the firm offers a unique set of tools called VirgoTrials that allows healthcare professionals to use this data to enroll patients for clinical trials. Virgo is presently associated with a number of major pharmaceutical trial sponsors and is being used by university medical centers, integrated health systems, and private practice networks. This funding will be used to develop the VirgoTrials platform and speed up distribution in the United States and overseas.

Virgo enables gastroenterologists and pulmonologists to use endoscopy footage for the betterment of patient care through new research and training efforts, in addition to speeding up clinical trials. The Virgo platform integrates multi-center research collaboration, video assessments, and the development and deployment of artificial intelligence solutions into one platform. Virgo is also a highly scalable solution, allowing health systems to quickly deploy across numerous facilities while maintaining direct connections with other EHR systems.

This investment will allow Virgo to expand its platform into new geographies and also new use cases. "Our initial focus with VirgoTrials has been on accelerating patient recruitment for inflammatory bowel disease studies, where we are recognizing fantastic results. With this financing, we will replicate our success in other disease areas and build new solutions to help trial sponsors realize the benefits of decentralized clinical trials for the many diseases where endoscopy plays a critical role. We believe the Virgo platform and clinical trial network has the potential to dramatically shorten trials and help get new treatments into the hands of patients faster," comments Matt Schwartz, CEO of Virgo.

Weekly Brief